| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Foreign currency transaction gain (loss) | -808 | - | - | - |
| Total other expense | -12,509 | -599 | -2,032 | -4,573 |
| Net loss | -26,829 | -15,378 | -19,343 | -19,374 |
| Deemed dividend related to warrant modifications | 353 | 560 | 265 | 132 |
| Net loss attributable to common stockholders | -27,182 | -15,938 | -19,608 | -19,506 |
| Foreign currency translation adjustment | -632 | 3,248 | 1,644 | - |
| Total comprehensive loss | -26,550 | -19,186 | -21,252 | - |
| Earnings per share, basic | -0.02 | -0.01 | -0.01 | -0.02 |
| Earnings per share, diluted | -0.02 | -0.01 | -0.01 | -0.02 |
| Weighted average number of shares outstanding, basic | 1,492,079 | 1,438,198 | 1,359,496 | 1,258,532 |
| Weighted average number of shares outstanding, diluted | 1,492,079 | 1,438,198 | 1,359,496 | 1,258,532 |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)